Karlijn Hummelink1,2, Vincent van der Noort3, Mirte Muller2, Robert D. Schouten2, Ferry Lalezari4, Dennis Peters5, Willemijn S. M. E. Theelen2, Viktor H. Koelzer6, Kirsten D. Mertz7, Alfred Zippelius8, Michel M. van den Heuvel2,11, Annegien Broeks5, John B. A. G. Haanen9, Ton N. Schumacher10, Gerrit A. Meijer1, Egbert F. Smit2,12, Kim Monkhorst1* and Daniela S. Thommen9* *These authors jointly supervised this work 1Department of Pathology, Division of Diagnostic Oncology, 2Department of Thoracic Oncology, Division of Medical Oncology, 3Department of Biometrics, 4Department of Radiology, Division of Diagnostic Oncology, 5Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands, 6Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, 7Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland, 8Department of Biomedicine, University Hospital Basel, Basel, Switzerland, 9Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, The Netherlands, 10Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands, 11Present address: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands, 12Present address: Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands. Clinical Cancer Research, 2022 Chapter 2 PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC
RkJQdWJsaXNoZXIy MTk4NDMw